Arcellx Revenue and Competitors
Estimated Revenue & Valuation
- Arcellx's estimated annual revenue is currently $42.2M per year.
- Arcellx's estimated revenue per employee is $193,750
- Arcellx's total funding is $200M.
Employee Data
- Arcellx has 218 Employees.
- Arcellx grew their employee count by 22% last year.
Arcellx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman & CEO | Reveal Email/Phone |
2 | Chief Counsel | Reveal Email/Phone |
3 | Head Medical Affairs | Reveal Email/Phone |
4 | VP Cell Process Science | Reveal Email/Phone |
5 | Head MSAT | Reveal Email/Phone |
6 | Head Value & Access | Reveal Email/Phone |
7 | VP, Clinical Research and Regulatory Affairs | Reveal Email/Phone |
8 | VP Quality | Reveal Email/Phone |
9 | VP, Quality | Reveal Email/Phone |
10 | Controller | Reveal Email/Phone |
Arcellx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | 0% | N/A | N/A |
#2 | $3.6M | 46 | -31% | $17.5M | N/A |
#3 | $3.6M | 46 | -34% | $10.5M | N/A |
#4 | $30.2M | 156 | 0% | $69.4M | N/A |
#5 | $11.8M | 76 | -15% | N/A | N/A |
#6 | $1.7M | 11 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $8.8M | 57 | 19% | N/A | N/A |
#9 | $0.2M | 1 | -86% | N/A | N/A |
#10 | $2M | 13 | 18% | N/A | N/A |
What Is Arcellx?
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.
keywords:N/A
$200M
Total Funding
218
Number of Employees
$42.2M
Revenue (est)
22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Arcellx News
According to Zacks, analysts expect that Arcellx will report full-year earnings of ($4.52) per share for the current financial year,...
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid...
About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies...
Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing. The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, C ...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $39.5M | 255 | 41% | N/A |
#2 | $95.4M | 288 | 57% | $228M |
#3 | $109.1M | 301 | N/A | N/A |
#4 | $100.1M | 364 | 3944% | N/A |
#5 | $69.6M | 371 | 13% | N/A |